Global cytokine analysis in myeloproliferative disorders.
Recently developed human cytokine array membranes combine the individual assets of enzyme-linked immunosorbent assay, enhanced chemiluminescence, and the high-throughput of microspot in order to detect multiple plasma cytokines simultaneously. We employed such a system to evaluate the presence and quantity of 79 different cytokines in the plasma of 20 patients with myeloproliferative disorders (MPDs) that were not on active therapy: 10 with primary myelofibrosis (PMF), 5 with polycythemia vera (PV), and 5 with essential thrombocythemia (ET). Compared to healthy controls, patients with PMF, but not those with either PV or ET, displayed significantly higher levels of tissue inhibitor of metalloproteinase (TIMP-1), macrophage inflammatory protein-1beta (MIP-1beta), and insulin-like growth factor binding factor-2 (IGFBP-2) (p=0.013, 0.028 and 0.02, respectively). These results constitute an important conformation for the pathogenetic role of these cytokines in PMF.
Ho
Ching-Liang
CL
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Lasho
Terra L
TL
Butterfield
Joseph H
JH
Tefferi
Ayalew
A
D054407:Chemokine CCL4 / Q000097:blood; D016207:Cytokines / Q000097:blood*; D006801:Humans; D007158:Immunologic Techniques; D018971:Insulin-Like Growth Factor Binding Protein 2 / Q000097:blood; D009196:Myeloproliferative Disorders / Q000097:blood*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood; D015854:Up-Regulation
D054407:Chemokine CCL4; D016207:Cytokines; D018971:Insulin-Like Growth Factor Binding Protein 2; D019715:Tissue Inhibitor of Metalloproteinase-1